Document -
Sobi receives positive CHMP opinion for Kineret® for treatment of rare disease CAPS
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of Kineret for the treatment of patients with Cryopyrin-Associated Periodic Syndromes (CAPS).
- License:
- Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
- File format:
